{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:34:12Z","timestamp":1794479652754,"version":"4.9.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.isci.2026.117854","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:49:10Z","timestamp":1791859750000},"page":"117854","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative systems pharmacology modeling of class I\u2013III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design"],"prefix":"10.1016","volume":"29","author":[{"given":"Jingjing","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenle","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-4452","authenticated-orcid":false,"given":"Guohua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117854_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1141876","article-title":"Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review","volume":"13","author":"Puri","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib2","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.lungcan.2021.06.002","article-title":"The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer","volume":"160","author":"Melosky","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.isci.2026.117854_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1535370220959657","article-title":"Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database","volume":"246","author":"Owsley","year":"2021","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.isci.2026.117854_bib4","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/cncr.29042","article-title":"Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium","volume":"121","author":"Villaruz","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.117854_bib5","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations","volume":"29","author":"Marchetti","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117854_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","article-title":"BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition","volume":"28","author":"Yao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.117854_bib8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2021.02.036","article-title":"BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy","volume":"149","author":"Wiesweg","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2026.117854_bib9","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2010.33.1280","article-title":"Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations","volume":"29","author":"Paik","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib10","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1097\/JTO.0000000000000344","article-title":"Clinical characteristics and course of 63 patients with BRAF mutant lung cancers","volume":"9","author":"Litvak","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117854_bib12","article-title":"BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective","volume":"12","author":"Yan","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071823","article-title":"BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117854_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11091388","article-title":"BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives","volume":"11","author":"Crispo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.117854_bib15","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.601722","article-title":"Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer","volume":"11","author":"Grassi","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.thorsurg.2014.12.003","article-title":"National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Lung Cancer Screening","volume":"25","author":"Wood","year":"2015","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.isci.2026.117854_bib19","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41388-017-0035-9","article-title":"Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers","volume":"37","author":"Kotani","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117854_bib20","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20241147","article-title":"PTPN23-dependent activation of PI3KC2\u03b1 is a therapeutic vulnerability of BRAF-mutant cancers","volume":"222","author":"He","year":"2025","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117854_bib21","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41401-024-01232-9","article-title":"Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities","volume":"45","author":"Zhou","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2026.117854_bib22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/164_2024_735","article-title":"Quantitative Systems Pharmacology Modeling in Immuno-Oncology: Hypothesis Testing, Dose Optimization, and Efficacy Prediction","volume":"289","author":"Wang","year":"2025","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.isci.2026.117854_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41698-023-00405-9","article-title":"Generating immunogenomic data-guided virtual patients using a QSP model to predict response of advanced NSCLC to PD-L1 inhibition","volume":"7","author":"Wang","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib24","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10928-024-09903-0","article-title":"Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling","volume":"51","author":"Schirru","year":"2024","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.isci.2026.117854_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41540-017-0016-1","article-title":"Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model","volume":"3","author":"Kirouac","year":"2017","journal-title":"NPJ Syst. Biol. Appl."},{"key":"10.1016\/j.isci.2026.117854_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110634","article-title":"Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF\/MEK inhibitor combination therapy","volume":"39","author":"Rajkumar","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2026.117854_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10262","article-title":"Mechanism of FGF receptor dimerization and activation","volume":"7","author":"Sarabipour","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117854_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005697","article-title":"EGFR-activated Src family kinases maintain GAB1-SHP2 complexes distal from EGFR","volume":"8","author":"Furcht","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.isci.2026.117854_bib29","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1038\/onc.2012.240","article-title":"Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations","volume":"32","author":"Furcht","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117854_bib30","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3892\/ijo.2015.2871","article-title":"EGF-stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib-resistant human lung cancer cell line","volume":"46","author":"Nishimura","year":"2015","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2013.09.028","article-title":"Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma","volume":"439","author":"Xu","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.isci.2026.117854_bib32","article-title":"Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC","volume":"6","author":"Cao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117854_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13046-017-0534-0","article-title":"FGF2\/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells","volume":"36","author":"Yuan","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117854_bib34","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1038\/s41388-018-0311-3","article-title":"FGFR1-ERK1\/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer","volume":"37","author":"Wang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.117854_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1478-811X-12-34","article-title":"Deciphering the mechanism behind Fibroblast Growth Factor (FGF) induced biphasic signal-response profiles","volume":"12","author":"Kanodia","year":"2014","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.isci.2026.117854_bib36","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2020.05.021","article-title":"Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations","volume":"15","author":"Negrao","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib37","doi-asserted-by":"crossref","first-page":"E748","DOI":"10.1073\/pnas.1320956111","article-title":"Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer","volume":"111","author":"Lin","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117854_bib38","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1038\/s41467-020-18123-2","article-title":"Inhibitors of BRAF dimers using an allosteric site","volume":"11","author":"Cotto-Rios","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117854_bib39","doi-asserted-by":"crossref","first-page":"60094","DOI":"10.18632\/oncotarget.11635","article-title":"Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib","volume":"8","author":"Noeparast","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117854_bib40","doi-asserted-by":"crossref","first-page":"16110","DOI":"10.18632\/oncotarget.24576","article-title":"Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer","volume":"9","author":"Noeparast","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2026.117854_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12935-022-02723-7","article-title":"In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation","volume":"23","author":"Chen","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.isci.2026.117854_bib42","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.21873\/anticanres.16992","article-title":"SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway","volume":"44","author":"Choi","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.isci.2026.117854_bib43","article-title":"Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study","volume":"3","author":"Subbiah","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.690","article-title":"623P Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12","volume":"35","author":"Lin","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(16)00077-2","article-title":"Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib46","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","article-title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","volume":"31","author":"Mazieres","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib47","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1158\/1078-0432.CCR-19-3443","article-title":"Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)","volume":"26","author":"Johnson","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117854_bib48","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib49","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","article-title":"Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis","volume":"17","author":"Planchard","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib50","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117854_bib51","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.117854_bib52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/nm.4369","article-title":"An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer","volume":"23","author":"Xue","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117854_bib53","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1158\/2159-8290.CD-23-0361","article-title":"SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy","volume":"13","author":"Drilon","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.117854_bib54","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1200\/JCO.2016.34.15_suppl.2517","article-title":"Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study","volume":"34","author":"Sen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.166061","article-title":"BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600\u0395 CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis","volume":"1867","author":"Koumaki","year":"2021","journal-title":"Biochim. Biophys. Acta. Mol. Basis Dis."},{"key":"10.1016\/j.isci.2026.117854_bib56","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.2019.37.15_suppl.3000","article-title":"Belvarafenib, a novel pan-RAF inhibitor, in solid tumor patients harboring BRAF, KRAS, or NRAS mutations: Phase I study","volume":"37","author":"Kim","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib57","doi-asserted-by":"crossref","first-page":"A095","DOI":"10.1158\/1535-7163.TARG-23-A095","article-title":"Abstract A095: The paradox-breaker BRAF inhibitor plixorafenib (FORE8394) efficiently inhibits non-V600 mutations and fusions","volume":"22","author":"Cohen","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.isci.2026.117854_bib58","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-18-1795","article-title":"Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition","volume":"24","author":"Johnson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117854_bib59","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-17-3384","article-title":"Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas","volume":"24","author":"Dankner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.117854_bib60","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.cllc.2019.02.022","article-title":"Clinical Benefit From BRAF\/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report","volume":"20","author":"Reyes","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.isci.2026.117854_bib61","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cllc.2019.03.007","article-title":"Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort","volume":"20","author":"Dudnik","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.isci.2026.117854_bib62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cpt.3298","article-title":"Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper","volume":"116","author":"Samineni","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.117854_bib63","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1074\/mcp.M113.037309","article-title":"A \u201cproteomic ruler\u201d for protein copy number and concentration estimation without spike-in standards","volume":"13","author":"Wi\u015bniewski","year":"2014","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.isci.2026.117854_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114339","article-title":"Lung cancer volume doubling time by computed tomography: A systematic review and meta-analysis","volume":"212","author":"Jiang","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.isci.2026.117854_bib65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.crad.2014.03.020","article-title":"Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy","volume":"69","author":"Nishino","year":"2014","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.isci.2026.117854_bib66","article-title":"Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","volume":"6","author":"Klute","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib67","article-title":"Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study","volume":"8","author":"Sahai","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.isci.2026.117854_bib68","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/psp4.12063","article-title":"Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models","volume":"5","author":"Allen","year":"2016","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.isci.2026.117854_bib69","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"Marino","year":"2008","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.isci.2026.117854_bib70","doi-asserted-by":"crossref","first-page":"500","DOI":"10.7334\/psicothema2013.23","article-title":"Using the R-MAPE index as a resistant measure of forecast accuracy","volume":"25","author":"Monta\u00f1o","year":"2013","journal-title":"Psicothema"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226032359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226032359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:19:16Z","timestamp":1794478756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226032359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":70,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589004226032359"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117854","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative systems pharmacology modeling of class I\u2013III BRAF-mutant NSCLC enables subgroup treatment analysis and combination therapy design","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117854","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117854"}}